journal article·2022-12Open access

The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis

Wanwan Yi, Tingting Qiao, Ziyu Yang, Lei Hu, Mingming Sun, Hengwei Fan, Yanping Xu, Zhongwei Lv

Abstract

Although the role of fibrinogen-like protein 1 (FGL1) in tumorigenesis is well known, a pan-cancer analysis of FGL1 lacks. We used bioinformatics techniques to analyze cancer data from publicly available datasets from The Cancer Genome Atlas, UALCAN, TIMER, Gene Expression Profiling Interactive Analysis, cBioPortal, Search Tool for the Retrieval of Interacting Genes, and DAVID. FGL1 expression was significantly regulated in various common tumors than in normal tissues; it was increased in lung adenocarcinoma and decreased in colon adenocarcinoma. Cox regression analysis demonstrated that the upregulation of FGL1 expression was correlated with poor overall survival (OS) and disease-free survival (DFS) in stomach adenocarcinoma, brain low-grade glioma, cervical squamous cell carcinoma, and endocervical adenocarcinoma. Decreased FGL1 methylation levels were observed in majority of tumor types. FGL1 expression was significantly associated with the levels of immune cell subtypes and immune checkpoint genes. Deep deletion was the most common genetic mutation in FGL1 that led to frame-shift mutations, which was closely associated with poor progression-free interval, disease-specific survival, and OS in patients with FGL1 mutations. Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that FGL1-related genes participate in diverse pathways. Ubiquitin-mediated proteolysis is significantly correlated to the function of FGL1, which was identified for the first time in the present study. This pan-cancer study provides a deep understanding of the functions of FGL1 in progression of many tumors and demonstrates that FGL1 may be a potential biomarker for the diagnosis, prognosis, and immune infiltration in cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Laser Design and Applications · Geophysics and Sensor Technology · Atmospheric and Environmental Gas Dynamics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Cancer treatment and survivorship statistics
3. Cancer statistics
4. The cancer genome atlas pan-cancer analysis project10.1038/ng.2764 ↗
5. Immunological role and prognostic value of apbb1ip in pan-cancer analysis10.7150/jca.50785 ↗
6. Comprehensive pan-cancer analysis confirmed that atg5 promoted the maintenance of tumor metabolism and the occurrence of tumor immune escape
7. Pan-cancer analysis of the dna methylation patterns of long non-coding rna10.1016/j.ygeno.2022.110377 ↗
8. The role of fibrinogen-like proteins in cancer10.7150/ijbs.56748 ↗
9. Fibrinogen-like protein 1 (fgl1): the next immune checkpoint target10.1186/s13045-021-01161-8 ↗
10. Immune checkpoint lag3 and its ligand fgl1 in cancer
11. Fibrinogen-like protein 1 is a major immune inhibitory ligand of lag-310.1016/j.cell.2018.11.010 ↗
12. Expression and clinical significance of lag-3, fgl1, pd-l1 and cd8(+)t cells in hepatocellular carcinoma using multiplex quantitative analysis10.1186/s12967-020-02469-8 ↗
13. Immune checkpoint fgl1 expression of circulating tumor cells is associated with poor survival in curatively resected hepatocellular carcinoma
14. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development10.1016/j.bbrc.2015.07.078 ↗
15. Fibrinogenlikeprotein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis
16. Fgl1 as a novel mediator and biomarker of malignant progression in clear cell renal cell carcinoma10.3389/fonc.2021.756843 ↗
17. Loss of fgl1 induces epithelialmesenchymal transition and angiogenesis in lkb1 mutant lung adenocarcinoma
18. Fgl1 regulates acquired resistance to gefitinib by inhibiting apoptosis in non-small cell lung cancer10.1186/s12931-020-01477-y ↗
19. The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating myc-target genes10.21037/tlcr-22-151 ↗
20. Gepia: a web server for cancer and normal gene expression profiling and interactive analyses10.1093/nar/gkx247 ↗
21. Ualcan: a portal for facilitating tumor subgroup gene expression and survival analyses10.1016/j.neo.2017.05.002 ↗
22. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer10.18632/oncotarget.10533 ↗
23. Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal10.1126/scisignal.2004088 ↗
24. Prognoscan: a new database for meta-analysis of the prognostic value of genes10.1186/1755-8794-2-18 ↗
25. Upsetr: an r package for the visualization of intersecting sets and their properties10.1093/bioinformatics/btx364 ↗
26. Profiling tumor infiltrating immune cells with cibersort10.1007/978-1-4939-7493-1_12 ↗
27. Timer2.0 for analysis of tumor-infiltrating immune cells10.1093/nar/gkaa407 ↗
28. The string database in 2017: quality-controlled protein-protein association networks, made broadly accessible10.1093/nar/gkw937 ↗
29. Cytoscape: a software environment for integrated models of biomolecular interaction networks10.1101/gr.1239303 ↗
30. Systematic and integrative analysis of large gene lists using david bioinformatics resources10.1038/nprot.2008.211 ↗
31. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists10.1093/nar/gkn923 ↗
32. Coadministration of irgd peptide with ros-sensitive nanoparticles co-delivering sifgl1 and sipd-l1 enhanced tumor immunotherapy10.1016/j.actbio.2021.09.040 ↗
33. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using ph-responsive hybrid membrane-coated nanoparticles10.1186/s12951-021-00805-8 ↗
34. Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine10.3389/fonc.2017.00052 ↗
35. Dual-targeting vaccine of fgl1/caix exhibits potent anti-tumor activity by activating dc-mediated multi-functional cd8 t cell immunity10.1016/j.omto.2021.11.017 ↗
36. Combinatorial patterns of somatic gene mutations in cancer10.1096/fj.08-108985 ↗
37. Dna methylation profiling in the clinic: applications and challenges10.1038/nrg3270 ↗
38. Deciphering the genetic code of dna methylation
39. Demethylation and up-regulation of an oncogene after hypomethylating therapy10.1056/NEJMoa2119771 ↗
40. Tumor immunosurveillance in human cancers10.1007/s10555-011-9270-7 ↗
41. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures10.1016/j.immuni.2013.07.008 ↗
42. Mutations associated with acquired resistance to pd-1 blockade in melanoma10.1056/NEJMoa1604958 ↗
43. Neoadjuvant pd-1 blockade in resectable lung cancer10.1056/NEJMoa1716078 ↗
44. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways10.1038/s41571-021-00552-7 ↗
45. Enhancing anti-tumour efficacy with immunotherapy combinations10.1016/S0140-6736(20)32598-8 ↗
46. Context-dependent functions of pattern recognition receptors in cancer10.1038/s41568-022-00462-5 ↗
47. Survival and biomarker analyses from the opacin-neo and opacin neoadjuvant immunotherapy trials in stage iii melanoma10.1038/s41591-020-01211-7 ↗